Pay in 4 interest-free payments of $5.02 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
It has been extensively characterised in preclinical in-vitro and in-vivo models for its cytoprotective, angiogenic, and anti-inflammatory properties across a range of tissue types
USP Compounding Standards and Beyond-Use Dates (BUDs) (PDF)
Key facts: First studied by researchers at the University of Zagreb (Croatia) in the early 1990s Over 100 peer-reviewed studies published since then (Kang et al., 2021) Administered via subcutaneous injection (most common), intramuscular injection, or orally Typical research dosages: 200-800 mcg per day Classification: Research peptide, not approved by the FDA for human use How it works (simplified): BPC-157 appears to promote healing by improving blood flow to damaged tissue, reducing inflammation, and supporting the body's natural repair processes
Peptides for menopause symptom management may complement tirzepatide therapy in perimenopausal and postmenopausal women
Dose , delivery method (injectable, topical, oral) and goal (skin, hair, healing) must match - get one wrong and the peptide still works , but never quite transforms
BPC-157 20mg Strength: 20 mg CAS: 137525-51-0 Chemical Formula: CHNO Molecular weight: 1419.5 g/mol Peptide Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val Synonyms: BPC157, Bepecin Storage: Store 28 C (20 C long-term)
US$ 28.77
US$ 23.78
US$ 21.76
US$ 27.67
